Effect of montelukast for treatment of asthma in cigarette smokers
(2013) In Journal of Allergy and Clinical Immunology 131(3). p.763-771- Abstract
- Many asthmatic patients are unable to quit cigarettes; therefore information is needed on treatment options for smokers. This study evaluates 10 mg/d montelukast and 250 mu g of fluticasone propionate twice daily, each compared with placebo, in patients with self-reported active smoking (unable to quit) and asthma. Methods: Patients (ages 18-55 years, with asthma [>= 1 year], FEV1 of 60% to 90% of predicted value, airway reversibility [>= 12%], and self-reported active smoking [>= 0.5 to <= 2 packs per day]) were randomized (after a 3-week, single-blind, placebo, run-in period) to 1 of 3 parallel, 6-month, double-blind treatment arms. The primary efficacy end point was the percentage of days with asthma control during... (More)
- Many asthmatic patients are unable to quit cigarettes; therefore information is needed on treatment options for smokers. This study evaluates 10 mg/d montelukast and 250 mu g of fluticasone propionate twice daily, each compared with placebo, in patients with self-reported active smoking (unable to quit) and asthma. Methods: Patients (ages 18-55 years, with asthma [>= 1 year], FEV1 of 60% to 90% of predicted value, airway reversibility [>= 12%], and self-reported active smoking [>= 0.5 to <= 2 packs per day]) were randomized (after a 3-week, single-blind, placebo, run-in period) to 1 of 3 parallel, 6-month, double-blind treatment arms. The primary efficacy end point was the percentage of days with asthma control during treatment. Adverse experiences (AEs) were also evaluated. Results: There were 347, 336, and 336 patients randomized to montelukast, fluticasone, and placebo, respectively. The mean percentage of days with asthma control over 6 months of treatment was 45% (montelukast, P < .05 vs placebo), 49% (fluticasone, P < .001 vs placebo), and 39% (placebo); the difference between montelukast and fluticasone was not significant (P = .14). Patients with a smoking history of <= 11 pack years (the median value) tended to show more benefit with fluticasone, whereas those with a smoking history of >11 pack years tended to show more benefit with montelukast. AEs occurred in similar proportions among treatment groups. Conclusions: In a population of asthmatic patients actively smoking cigarettes, both 10 mg/d montelukast and 250 mu g of fluticasone propionate twice daily significantly increased the mean percentage of days with asthma control compared with placebo. (J Allergy Clin Immunol 2013;131:763-71.) (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3657305
- author
- Price, David ; Popov, Todor A. ; Bjermer, Leif LU ; Lu, Susan ; Petrovic, Romana ; Vandormael, Kristel ; Mehta, Anish ; Strus, Jolanta D. ; Polos, Peter G. and Philip, George
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Montelukast, smoking, fluticasone propionate, leukotriene receptor, antagonist, asthma control, corticosteroids
- in
- Journal of Allergy and Clinical Immunology
- volume
- 131
- issue
- 3
- pages
- 763 - 771
- publisher
- Elsevier
- external identifiers
-
- wos:000315587800018
- scopus:84875220579
- pmid:23380218
- ISSN
- 1097-6825
- DOI
- 10.1016/j.jaci.2012.12.673
- language
- English
- LU publication?
- yes
- id
- 4402a073-96de-4c5b-8400-dd9781f6d652 (old id 3657305)
- date added to LUP
- 2016-04-01 14:36:40
- date last changed
- 2022-03-22 00:56:45
@article{4402a073-96de-4c5b-8400-dd9781f6d652,
abstract = {{Many asthmatic patients are unable to quit cigarettes; therefore information is needed on treatment options for smokers. This study evaluates 10 mg/d montelukast and 250 mu g of fluticasone propionate twice daily, each compared with placebo, in patients with self-reported active smoking (unable to quit) and asthma. Methods: Patients (ages 18-55 years, with asthma [>= 1 year], FEV1 of 60% to 90% of predicted value, airway reversibility [>= 12%], and self-reported active smoking [>= 0.5 to <= 2 packs per day]) were randomized (after a 3-week, single-blind, placebo, run-in period) to 1 of 3 parallel, 6-month, double-blind treatment arms. The primary efficacy end point was the percentage of days with asthma control during treatment. Adverse experiences (AEs) were also evaluated. Results: There were 347, 336, and 336 patients randomized to montelukast, fluticasone, and placebo, respectively. The mean percentage of days with asthma control over 6 months of treatment was 45% (montelukast, P < .05 vs placebo), 49% (fluticasone, P < .001 vs placebo), and 39% (placebo); the difference between montelukast and fluticasone was not significant (P = .14). Patients with a smoking history of <= 11 pack years (the median value) tended to show more benefit with fluticasone, whereas those with a smoking history of >11 pack years tended to show more benefit with montelukast. AEs occurred in similar proportions among treatment groups. Conclusions: In a population of asthmatic patients actively smoking cigarettes, both 10 mg/d montelukast and 250 mu g of fluticasone propionate twice daily significantly increased the mean percentage of days with asthma control compared with placebo. (J Allergy Clin Immunol 2013;131:763-71.)}},
author = {{Price, David and Popov, Todor A. and Bjermer, Leif and Lu, Susan and Petrovic, Romana and Vandormael, Kristel and Mehta, Anish and Strus, Jolanta D. and Polos, Peter G. and Philip, George}},
issn = {{1097-6825}},
keywords = {{Montelukast; smoking; fluticasone propionate; leukotriene receptor; antagonist; asthma control; corticosteroids}},
language = {{eng}},
number = {{3}},
pages = {{763--771}},
publisher = {{Elsevier}},
series = {{Journal of Allergy and Clinical Immunology}},
title = {{Effect of montelukast for treatment of asthma in cigarette smokers}},
url = {{http://dx.doi.org/10.1016/j.jaci.2012.12.673}},
doi = {{10.1016/j.jaci.2012.12.673}},
volume = {{131}},
year = {{2013}},
}